Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

EXPRESSION OF p-STAT3 IN GASTRIC CANCER TISSUES AND ITS ASSOCIATION WITH SELECTED LABORATORY PARAMETERS

Nguyen Thi Mai Ly1,2, Tran Doanh Hieu2,3, Le Thanh Son2,3, Bui Khac Cuong4,5
1 Military Hospital 103
2 Bệnh viện Quân y 103
3 103 Military Hospital
4 108 Military Central Hospital
5 Bệnh viện Trung ương Quân đội 108
DOI: 10.52163/yhc.v67iCD12.6135
645 Views
0 Downloads
Keywords
Gastric cancer, p-STAT3, immunohistochemistry, hemoglobin, hematocrit.
Abstract

Objectives: To determine the expression of p-STAT3 in gastric cancer tissues and evaluate its association with selected laboratory parameters in the study population.

Subjects and methods: A descriptive analytical study was conducted on 68 patients with gastric adenocarcinoma. p-STAT3 expression was assessed by immunohistochemistry. Laboratory parameters were compared between groups using the Mann-Whitney U test.

Results: The rate of positive p-STAT3 expression was 32.35%. The p-STAT3-positive group had significantly lower hemoglobin levels than the p-STAT3-negative group [119.5 g/l (103.75-139.25) vs. 136.0 g/l (125.75-148.25); p = 0.020] and lower hematocrit values [0.36 l/l (0.31-0.41) vs. 0.41 l/l (0.37-0.44); p = 0.019]. Red blood cell counts tended to be lower in the p-STAT3-positive group, although the difference was not statistically significant (p = 0.082). No significant differences were observed in other biochemical parameters (p > 0.05).

Conclusions: p-STAT3 was expressed in 32.35% of gastric cancer cases. Positive p-STAT3 expression was associated with lower hemoglobin and hematocrit levels in patients with gastric cancer.

References
[1]
Bray F, Laversanne M, Sung H, Ferlay J, Siegel R.L, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74 (3): 229-63. Google Scholar
[2]
Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res, 2024, 43 (1): 23. Google Scholar
[3]
Yu S, Li G, Wang Z, Wang Z, Chen C, Cai S et al. The prognostic value of pSTAT3 in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol, 2016, 142 (3): 649-57. Google Scholar
[4]
Arshad S, Naveed M, Ullia M, Javed K, Butt A, Khawar M et al. Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges. Genet Mol Biol, 2020, 43 (1): e20180160. Google Scholar
[5]
Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications. PLoS One, 2013, 8 (10): e75788. Google Scholar
[6]
Yoon J, Cho SJ, Ko Y.S, Park J, Shin D.H, Hwang I.C et al. A synergistic interaction between transcription factors nuclear factor-kappaB and signal transducers and activators of transcription 3 promotes gastric cancer cell migration and invasion. BMC Gastroenterol, 2013, 13: 29. Google Scholar
[7]
Zhao G, Zhu G, Huang Y, Zheng W, Hua J, Yang S et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol Rep, 2016, 35 (3): 1787-95. Google Scholar
[8]
Deng J.Y, Sun D, Liu X.Y, Pan Y, Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol, 2010, 16 (42): 5380-7. Google Scholar
[9]
Song Y.Y, Sun L.D, Liu M.L, Liu Z.L, Chen F, Zhang Y.Z et al. STAT3, p-STAT3 and HIF-1alpha are associated with vasculogenic mimicry and impact on survival in gastric adenocarcinoma. Oncol Lett, 2014, 8 (1): 431-7. Google Scholar
[10]
Wrighting D.M, Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood, 2006, 108 (9): 3204-9. Google Scholar